Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

159.72
+2.781.77%
Volume:1.48M
Turnover:234.88M
Market Cap:247.72B
PE:23.91
High:159.95
Open:157.68
Low:157.23
Close:156.94
52wk High:212.71
52wk Low:145.79
Shares:1.55B
Float Shares:1.50B
Volume Ratio:0.67
T/O Rate:0.10%
Dividend:3.17
Dividend Rate:1.98%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.02%
PB:4.93
PE(LYR):24.42

Loading ...

AstraZeneca PLC Stock Falls Thursday, Underperforms Market

Dow Jones
·
Aug 07

AstraZeneca May Abandon Decade-Long M&A Strategy, Pursuing Mega Deal to Secure US Market Scale

Deep News
·
Aug 06

Deal or no Deal, AstraZeneca Stock is a Bargain

Dow Jones
·
Aug 06

AstraZeneca, Jaguar Land Rover Gain Access to UK's Fast-Track Visa

MT Newswires Live
·
Aug 06

Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence

Reuters
·
Aug 05

Unusually active option classes on open August 5th

TIPRANKS
·
Aug 05

Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports

TIPRANKS
·
Aug 05

AstraZeneca PLC Stock (AZN) Moved Up by 4.30% on Aug 5: A Full Analysis

TradingKey
·
Aug 05

Movement Alert|AstraZeneca PLC Rises 4.97% in Regular Trading, Rebound After Bristol Myers Merger Rumor Officially Denied

Market Focus
·
Aug 05

Market Chatter: AstraZeneca, Bristol Myers Not Pursuing Merger Talks

MT Newswires Live
·
Aug 05

Movement Alert|AstraZeneca PLC Pre-Market Rise 4.77%, Stock Recovers as Multiple Banks Question Feasibility of Bristol-Myers Squibb Merger

Market Focus
·
Aug 05

AstraZeneca deal talks with Bristol Myers remain active, Semafor says

TIPRANKS
·
Aug 05

AstraZeneca Advances Tuesday, Outperforms Market

Dow Jones
·
Aug 05

Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says

MT Newswires Live
·
Aug 04

AstraZeneca (AZN) Gets a Sell from Deutsche Bank

TIPRANKS
·
Aug 04

AstraZeneca (AZN) Receives a Buy from UBS

TIPRANKS
·
Aug 04

More Biotech M&A is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Dow Jones
·
Aug 04

A $400 Billion Pharma Merger? RBC Says Don't Bet On It

Options & Short Sell
·
Aug 04

An AstraZeneca, Bristol Myers Squibb Merger Could Create a Cancer-Drug Giant, but Analysts Call it 'odd'

Dow Jones
·
Aug 04

TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

TIPRANKS
·
Aug 04